New Aurigene biologics facility opens in Hyderabad, India

Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley.

A Dr Reddy’s Laboratories Limited company, Aurigene’s new biologics facility spans 70,000 sq. ft. The facility will offer process and analytical development as well as small scale manufacturing of antibodies and other recombinant proteins for both preclinical and early phase clinical needs. As of now, the process and analytical development labs are operational, while manufacturing capacity will be completed later this year. 

The new facility will complement Aurigene’s existing discovery capabilities and infrastructure, which focus on recombinant proteins. These include monoclonal antibodies, bi- and multi-specifics, immune-fusion molecules, and antibody drug conjugates. With end-to-end services delivering solutions from discovery through to commercial manufacturing, the new Genome Valley facility aims to deliver compliant and economically viable process development solutions and support analytical methods for their customers.  

CEO of Aurigene Akhil Ravi commented “The journey started a year back when we decided to invest in creating the facility. It is great to see the facility operational and the addition of this capacity and capabilities shows our firm commitment to the continued expansion of our biologics business, building on 25 years of proven experience. The state-of-the-art facility will enable us to service our global customers efficiently and support in the development of innovative medicine.” 

Akhil Ravi, CEO of Aurigene

The opening of the Hyderabad facility forms part of multiple strategic initiatives Aurigene hopes to implement as part of their rapid growth in small molecules and biologics. Recently, the company announced AI and ML-led drug discovery in small molecules and a collaboration with Vipergen, a DNA-encoded library technology service provider.  

Dr Roger Lias, Global Commercial Head – Biologics at Aurigene, stated “There are very few global CDMOs that can truly support customers ‘end-to-end' from discovery services to large-scale commercial manufacture of both Drug Substance and Drug Product. Our new facility further strengthens Aurigene’s capabilities and builds on our technical excellence, demonstrated global compliance, and state-of-the-art facilities as companies from start-up biotechs to global multinationals continue to strengthen their supply chains and seek economically viable support for both their development portfolios and marketed products.” 
Dr Roger Lias, Global Commercial Head - Biologics at Aurigene